Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk - PubMed (original) (raw)
. 2006 Jul 4;48(1):193-202.
doi: 10.1016/j.jacc.2006.03.042. Epub 2006 May 5.
Affiliations
- PMID: 16814667
- DOI: 10.1016/j.jacc.2006.03.042
Free article
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk
Michael Joner et al. J Am Coll Cardiol. 2006.
Free article
Abstract
Objectives: This study examined human drug-eluting stents (DES) to determine the long-term effects of these stents on coronary arterial healing and identified mechanisms underlying late stent thrombosis (LST).
Background: Although DES reduce the need for repeat revascularization compared with bare-metal stents (BMS), data suggest the window of thrombotic risk for Cypher (Cordis Corp., Miami Lakes, Florida) and Taxus (Boston Scientific Corp., Natick, Massachusetts) DES extends far beyond that for BMS.
Methods: From a registry of 40 autopsies of DES (68 stents), 23 DES cases of >30 days duration were compared with 25 matched autopsies of BMS implantation. Late stent thrombosis was defined as an acute thrombus within a stent >30 days old.
Results: Of 23 patients with DES >30 days old, 14 had evidence of LST. Cypher and Taxus DES showed greater delayed healing characterized by persistent fibrin deposition (fibrin score 2.3 +/- 1.1 vs. 0.9 +/- 0.8, p = 0.0001) and poorer endothelialization (55.8 +/- 26.5%) compared with BMS (89.8 +/- 20.9, p = 0.0001). Moreover, DES with LST showed more delayed healing compared with patent DES. In 5 of 14 patients suffering LST, antiplatelet therapy had been withdrawn. Additional procedural and pathologic risk factors for LST were: 1) local hypersensitivity reaction; 2) ostial and/or bifurcation stenting; 3) malapposition/incomplete apposition; 4) restenosis; and 5) strut penetration into a necrotic core.
Conclusions: The Cypher and Taxus DES result in delayed arterial healing when compared with BMS of similar implant duration. The cause of DES LST is multifactorial with delayed healing in combination with other clinical and procedural risk factors playing a role.
Comment in
- Drug-eluting stent thrombosis: increasingly recognized but too frequently overemphasized.
Colombo A, Corbett SJ. Colombo A, et al. J Am Coll Cardiol. 2006 Jul 4;48(1):203-5. doi: 10.1016/j.jacc.2006.04.040. Epub 2006 May 5. J Am Coll Cardiol. 2006. PMID: 16814668 No abstract available.
Similar articles
- Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Finn AV, et al. Circulation. 2007 May 8;115(18):2435-41. doi: 10.1161/CIRCULATIONAHA.107.693739. Epub 2007 Apr 16. Circulation. 2007. PMID: 17438147 - Vascular pathology of drug-eluting stents.
Nakazawa G, Finn AV, Virmani R. Nakazawa G, et al. Herz. 2007 Jun;32(4):274-80. doi: 10.1007/s00059-007-2997-9. Herz. 2007. PMID: 17607533 Review. - Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
Marzocchi A, Saia F, Piovaccari G, Manari A, Aurier E, Benassi A, Cremonesi A, Percoco G, Varani E, Magnavacchi P, Guastaroba P, Grilli R, Maresta A. Marzocchi A, et al. Circulation. 2007 Jun 26;115(25):3181-8. doi: 10.1161/CIRCULATIONAHA.106.667592. Epub 2007 Jun 11. Circulation. 2007. PMID: 17562952 - Pathology of drug-eluting stents: implications for coronary intervention.
Finn AV, Nakazawa G, Virmani R. Finn AV, et al. Indian Heart J. 2007 Mar-Apr;59(2 Suppl B):B41-9. Indian Heart J. 2007. PMID: 19153436 - Late coronary stent thrombosis.
Thuesen L, Holm NR. Thuesen L, et al. Minerva Med. 2010 Feb;101(1):25-33. Minerva Med. 2010. PMID: 20228718 Review.
Cited by
- Shear- vs. nanotopography-guided control of growth of endothelial cells on RGD-nanoparticle-nanowell arrays.
McCracken KE, Tran PL, You DJ, Slepian MJ, Yoon JY. McCracken KE, et al. J Biol Eng. 2013 Apr 22;7(1):11. doi: 10.1186/1754-1611-7-11. J Biol Eng. 2013. PMID: 23607894 Free PMC article. - Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.
Steffens S, Pacher P. Steffens S, et al. Br J Pharmacol. 2012 Sep;167(2):313-23. doi: 10.1111/j.1476-5381.2012.02042.x. Br J Pharmacol. 2012. PMID: 22612332 Free PMC article. - Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Koni E, Wanha W, Ratajczak J, Zhang Z, Podhajski P, Musci RL, Sangiorgi GM, Kaźmierski M, Buffon A, Kubica J, Wojakowski W, Navarese EP. Koni E, et al. J Clin Med. 2021 Mar 19;10(6):1278. doi: 10.3390/jcm10061278. J Clin Med. 2021. PMID: 33808678 Free PMC article. - Detection of Blood Clots Using a Whole Stent as an Active Implantable Biosensor.
Kirimi MT, Hoare D, Holsgrove M, Czyzewski J, Mirzai N, Mercer JR, Neale SL. Kirimi MT, et al. Adv Sci (Weinh). 2024 Jun;11(21):e2304748. doi: 10.1002/advs.202304748. Epub 2024 Feb 11. Adv Sci (Weinh). 2024. PMID: 38342628 Free PMC article. - Reproducibility of qualitative assessment of stent struts coverage by optical coherence tomography.
Brugaletta S, Garcia-Garcia HM, Gomez-Lara J, Radu MD, Pawar R, Khachabi J, Bruining N, Sabaté M, Serruys PW. Brugaletta S, et al. Int J Cardiovasc Imaging. 2013 Jan;29(1):5-11. doi: 10.1007/s10554-012-0030-8. Epub 2012 Mar 14. Int J Cardiovasc Imaging. 2013. PMID: 22415543 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources